Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/836"
Predicate | Value (sorted: default) |
rdfs:label |
|
rdf:type |
|
?:Evidence_enzyme_system |
|
?:Evidence_type |
|
?:content |
"Drug Interactions
...
Amiodarone is also known to be an inhibitor of CYP3A4. Therefore, amiodarone has the potential for interactions with drugs or substances that may be substrates, inhibitors or inducers of CYP3A4. While only a limited number of in vivo drug-drug interactions with amiodarone have been reported, the potential for other interactions should be anticipated. This is especially important for drugs associated with serious toxicity, such as other antiarrhythmics. If such drugs are needed, their dose should be reassessed and, where appropriate, plasma concentration measured. In view of the long and variable half-life of amiodarone, potential for drug interactions exists, not only with concomitant medication, but also with drugs administered after discontinuation of amiodarone."
|
dc:creator |
|
dc:date |
"01/11/2010 16:35:31"
|
rdfs:seeAlso |
|
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ amiodarone_inhibits_cyp3a4, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1447 }
Context graph